Anti-tumor activity of the novel hexahydrocannabinol analog LYR-8 in human colorectal tumor xenograft is mediated through the inhibition of Akt and hypoxia-inducible factor-1α activation

Biological and Pharmaceutical Bulletin

Volumn 35, Issue 6, 2012, Pages 924-932

  Thapa, Dinesh ^a,d   Kang, Youra ^a   Park, Pil Hoon ^a   Noh, Seok Kyun ^a   Lee, Yong Rok ^a   Han, Sung Soo ^a   Ku, Sae Kwang ^b   Jung, Yunjin ^c   Kim, Jung Ae ^a  

^a Yeungnam University   (South Korea)

^b Daegu Haany University   (South Korea)

^c Pusan National University   (South Korea)

^d University of Texas Health Science Center   (United States)

Author keywords

Akt; Anti tumor; Cyclooxygenase 2; Hexahydrocannabinol; Hypoxia inducible factor 1 ; Vascular endothelial growth factor

Indexed keywords

CANNABINOID DERIVATIVE; COBALT CHLORIDE; CYCLOOXYGENASE 2; HYPOXIA INDUCIBLE FACTOR 1ALPHA; LYR 8; PROSTAGLANDIN E2; PROTEIN KINASE B; UNCLASSIFIED DRUG; VASCULOTROPIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INHIBITION; CELL STRAIN HT29; CHORIOALLANTOIS; COLORECTAL TUMOR; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG STRUCTURE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; PROTEIN EXPRESSION; TUMOR MICROENVIRONMENT; TUMOR XENOGRAFT;

EID: 84861857178     PISSN: 09186158     EISSN: 13475215     Source Type: Journal    
DOI: 10.1248/bpb.35.924     Document Type: Article

References (50)

1. Carmeliet P. Angiogenesis in health and disease. Nat. Med., 9, 653-660 (2003).
2. Folkman J. Angiogenesis: an organizing principle for drug discovery? Nat. Rev. Drug Discov., 6, 273-286 (2007).
3. Ferrara N. Role of vascular endothelial growth factor in physiologic and pathologic angiogenesis: therapeutic implications. Semin. Oncol., 29 (Suppl. 16), 10-14 (2002).
4. Wang GL, Jiang BH, Rue EA, Semenza GL. Hypoxia-inducible factor 1 is a basic-helix-loop-helix-PAS heterodimer regulated by cellular O2 tension. Proc. Natl. Acad. Sci. U.S.A., 92, 5510-5514 (1995).
5. Jiang BH, Rue E, Wang GL, Roe R, Semenza GL. Dimerization, DNA binding, and transactivation properties of hypoxia-inducible factor 1. J. Biol. Chem., 271, 17771-17778 (1996).
6. 2-dependent degradation domain via the ubiquitin-proteasome pathway. Proc. Natl. Acad. Sci. U.S.A., 95, 7987-7992 (1998).
7. Birner P, Schindl M, Obermair A, Breitenecker G, Oberhuber G. Expression of hypoxia-inducible factor 1alpha in epithelial ovarian tumors: its impact on prognosis and on response to chemotherapy. Clin. Cancer Res., 7, 1661-1668 (2001).
8. Zagzag D, Zhong H, Scalzitti JM, Laughner E, Simons JW, Semenza GL. Expression of hypoxia-inducible factor 1alpha in brain tumors: association with angiogenesis, invasion, and progression. Cancer, 88, 2606-2618 (2000).
9. Schindl M, Schoppmann SF, Samonigg H, Hausmaninger H, Kwasny W, Gnant M, Jakesz R, Kubista E, Birner P, Oberhuber G, Austrian Breast and Colorectal Cancer Study Group. Overexpression of hypoxia-inducible factor 1alpha is associated with an unfavorable prognosis in lymph node-positive breast cancer. Clin. Cancer Res., 8, 1831-1837 (2002).
10. Harris AL. Hypoxia - A key regulatory factor in tumour growth. Nat. Rev. Cancer, 2, 38-47 (2002).
11. Brown JM. Exploiting the hypoxic cancer cell: mechanisms and therapeutic strategies. Mol. Med. Today, 6, 157-162 (2000).
12. Semenza GL. Targeting HIF-1 for cancer therapy. Nat. Rev. Cancer, 3, 721-732 (2003).
13. Pouysségur J, Dayan F, Mazure NM. Hypoxia signalling in cancer and approaches to enforce tumour regression. Nature, 441, 437-443 (2006).
14. Lee YR, Xia LK. Efficient one-pot synthetic approaches for cannabinoid analogues and their application to biologically interesting (-)- hexahydrocannabinol and (+)-hexahydrocannabinol. Tetrahedron Lett., 49, 3283-3287 (2008).
15. Thapa D, Babu D, Park MA, Kwak MK, Lee YR, Kim JM, Kwon TK, Kim JA. Induction of p53-independent apoptosis by a novel synthetic hexahydrocannabinol analog is mediated via Sp1-dependent NSAID-activated gene-1 in colon cancer cells. Biochem. Pharmacol., 80, 62-71 (2010).
16. Thapa D, Lee JS, Heo SW, Lee YR, Kang KW, Kwak MK, Choi HG, Kim JA. Novel hexahydrocannabinol analogs as potential anticancer agents inhibit cell proliferation and tumor angiogenesis. Eur. J. Pharmacol., 650, 64-71 (2011).
17. Yeo EJ, Chun YS, Cho YS, Kim J, Lee JC, Kim MS, Park JW. YC-1: a potential anticancer drug targeting hypoxia-inducible factor 1. J. Natl. Cancer Inst., 95, 516-525 (2003).
18. Park BC, Park SY, Lee JS, Mousa SA, Kim JT, Kwak MK, Kang KW, Lee ES, Choi HG, Yong CS, Kim JA. The anti-angiogenic effects of 1-furan-2-yl-3-pyridin- 2-yl-propenone are mediated through the suppression of both VEGF production and VEGF-induced signaling. Vascul. Pharmacol., 50, 123-131 (2009).
19. Kim TH, Hur EG, Kang SJ, Kim JA, Thapa D, Lee YM, Ku SK, Jung Y, Kwak MK. NRF2 blockade suppresses colon tumor angiogenesis by inhibiting hypoxia-induced activation of HIF-1α. Cancer Res., 71, 2260-2275 (2011).
20. Galve-Roperh I, Sánchez C, Cortés ML, Gómez del Pulgar T, Izquierdo M, Guzmán M. Anti-tumoral action of cannabinoids: involvement of sustained ceramide accumulation and extracellular signal-regulated kinase activation. Nat. Med., 6, 313-319 (2000).
21. Sánchez C, de Ceballos ML, Gomez del Pulgar T, Rueda D, Corbacho C, Velasco G, Galve-Roperh I, Huffman JW, Ramón y Cajal S, Guzmán M. Inhibition of glioma growth in vivo by selective activation of the CB(2) cannabinoid receptor. Cancer Res., 61, 5784-5789 (2001).
22. Freimuth N, Ramer R, Hinz B. Antitumorigenic effects of cannabinoids beyond apoptosis. J. Pharmacol. Exp. Ther., 332, 336-344 (2010).
23. Blázquez C, Salazar M, Carracedo A, Lorente M, Egia A, González-Feria L, Haro A, Velasco G, Guzmán M. Cannabinoids inhibit glioma cell invasion by down-regulating matrix metalloproteinase-2 expression. Cancer Res., 68, 1945-1952 (2008).
24. Blázquez C, Casanova ML, Planas A, Gómez Del Pulgar T, Villanueva C, Fernández-Aceñero MJ, Aragonés J, Huffman JW, Jorcano JL, Guzmán M. Inhibition of tumor angiogenesis by cannabinoids. FASEB J., 17, 529-531 (2003).
25. Guzmán M, Sánchez C, Galve-Roperh I. Cannabinoids and cell fate. Pharmacol. Ther., 95, 175-184 (2002).
26. Bifulco M, Di Marzo V. Targeting the endocannabinoid system in cancer therapy: a call for further research. Nat. Med., 8, 547-550 (2002).
27. Liao D, Luo Y, Markowitz D, Xiang R, Reisfeld RA. Cancer associated fibroblasts promote tumor growth and metastasis by modulating the tumor immune microenvironment in a 4T1 murine breast cancer model. PLoS ONE, 4, e7965 (2009).
28. Pietras K, Ostman A. Hallmarks of cancer: interactions with the tumor stroma. Exp. Cell Res., 316, 1324-1331 (2010).
29. Sharma M, Beck AH, Webster JA, Espinosa I, Montgomery K, Varma S, van de Rijn M, Jensen KC, West RB. Analysis of stromal signatures in the tumor microenvironment of ductal carcinoma in situ. Breast Cancer Res. Treat., 123, 397-404 (2010).
30. Jubb AM, Harris AL. Biomarkers to predict the clinical efficacy of bevacizumab in cancer. Lancet Oncol., 11, 1172-1183 (2010).
31. Ferrara N. VEGF and the quest for tumour angiogenesis factors. Nat. Rev. Cancer, 2, 795-803 (2002).
32. Jain RK, Duda DG, Clark JW, Loeffler JS. Lessons from phase III clinical trials on anti-VEGF therapy for cancer. Nat. Clin. Pract. Oncol., 3, 24-40 (2006).
33. de Gramont A, Larsen AK, Tournigand C, Louvet C, André T, GERCOR (French Oncology Research Group). Update on targeted agents for adjuvant treatment of colon cancer in 2006. Gastrointest Cancer Res, 1 (Suppl. 2), S47-S49 (2007).
34. Kaidi A, Qualtrough D, Williams AC, Paraskeva C. Direct transcriptional up-regulation of cyclooxygenase-2 by hypoxia-inducible factor (HIF)-1 promotes colorectal tumor cell survival and enhances HIF-1 transcriptional activity during hypoxia. Cancer Res., 66, 6683-6691 (2006).
35. Lee JJ, Natsuizaka M, Ohashi S, Wong GS, Takaoka M, Michaylira CZ, Budo D, Tobias JW, Kanai M, Shirakawa Y, Naomoto Y, Klein-Szanto AJ, Haase VH, Nakagawa H. Hypoxia activates the cyclooxygenase-2-prostaglandin E synthase axis. Carcinogenesis, 31, 427-434 (2010).
36. Tjiu JW, Chen JS, Shun CT, Lin SJ, Liao YH, Chu CY, Tsai TF, Chiu HC, Dai YS, Inoue H, Yang PC, Kuo ML, Jee SH. Tumor-associated macrophage-induced invasion and angiogenesis of human basal cell carcinoma cells by cyclooxygenase-2 induction. J. Invest. Dermatol., 129, 1016-1025 (2009).
37. Yashiro M, Nakazawa K, Tendo M, Kosaka K, Shinto O, Hirakawa K. Selective cyclooxygenase-2 inhibitor downregulates the paracrine epithelial-mesenchymal interactions of growth in scirrhous gastric carcinoma. Int. J. Cancer, 120, 686-693 (2007).
38. Semenza GL. Evaluation of HIF-1 inhibitors as anticancer agents. Drug Discov. Today, 12, 853-859 (2007).
39. Welsh SJ, Williams RR, Birmingham A, Newman DJ, Kirkpatrick DL, Powis G. The thioredoxin redox inhibitors 1-methylpropyl 2-imidazolyl disulfide and pleurotin inhibit hypoxia-induced factor 1alpha and vascular endothelial growth factor formation. Mol. Cancer Ther., 2, 235-243 (2003).
40. Yewalkar N, Deore V, Padgaonkar A, Manohar S, Sahu B, Kumar P, Jalota-Badhwar A, Joshi KS, Sharma S, Kumar S. Development of novel inhibitors targeting HIF-1α towards anticancer drug discovery. Bioorg. Med. Chem. Lett., 20, 6426-6429 (2010).
41. Ban HS, Uto Y, Nakamura H. Hypoxia-inducible factor inhibitors: a survey of recent patented compounds (2004-2010). Expert Opin. Ther. Pat., 2, 131-146 (2010).
42. Alvarez-Tejado M, Naranjo-Suarez S, Jiménez C, Carrera AC, Landázuri MO, del Peso L. Hypoxia induces the activation of the phosphatidylinositol 3-kinase/Akt cell survival pathway in PC12 cells: protective role in apoptosis. J. Biol. Chem., 276, 22368-22374 (2001).
43. Kong D, Yamori T. Phosphatidylinositol 3-kinase inhibitors: promising drug candidates for cancer therapy. Cancer Sci., 99, 1734-1740 (2008).
44. Terzuoli E, Donnini S, Giachetti A, Iñiguez MA, Fresno M, Melillo G, Ziche M. Inhibition of hypoxia inducible factor-1alpha by dihydroxyphenylethanol, a product from olive oil, blocks microsomal prostaglandin-E synthase-1/vascular endothelial growth factor expression and reduces tumor angiogenesis. Clin. Cancer Res., 16, 4207-4216 (2010).
45. Liu L, Ning X, Han S, Zhang H, Sun L, Shi Y, Sun S, Guo C, Yin F, Qiao T, Wu K, Fan D. Hypoxia induced HIF-1 accumulation and VEGF expression in gastric epithelial mucosa cell: involvement of ERK1/2 and PI3K/Akt. Mol. Biol. (Mosk.), 42, 459-469 (2008).
46. Gately S, Li WW. Multiple roles of COX-2 in tumor angiogenesis: a target for antiangiogenic therapy. Semin. Oncol., 31 (Suppl. 7), 2-11 (2004).
47. Yi T, Yi Z, Cho SG, Luo J, Pandey MK, Aggarwal BB, Liu M. Gambogic acid inhibits angiogenesis and prostate tumor growth by suppressing vascular endothelial growth factor receptor 2 signaling. Cancer Res., 68, 1843-1850 (2008).
48. Singh RP, Gu M, Agarwal R. Silibinin inhibits colorectal cancer growth by inhibiting tumor cell proliferation and angiogenesis. Cancer Res., 68, 2043-2050 (2008).
49. Lu X, Kang Y. Hypoxia and hypoxia-inducible factors: master regulators of metastasis. Clin. Cancer Res., 16, 5928-5935 (2010).
50. Monti E, Gariboldi MB. HIF-1 as a target for cancer chemotherapy, chemosensitization and chemoprevention. Curr. Mol. Pharmacol., 4, 62-77 (2011).